Neoadjuvant JS001, or JS001 in Combination With Pemetrexed and Carboplatin in Resectable NSCLC. (NAJSCR)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03623776 |
Recruitment Status :
Active, not recruiting
First Posted : August 9, 2018
Last Update Posted : March 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Efficacy and Safety | Drug: JS001 Drug: Pemetrexed Drug: Carboplatin Procedure: Thoracic Surgery | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 80 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC. |
Actual Study Start Date : | February 1, 2019 |
Estimated Primary Completion Date : | March 1, 2021 |
Estimated Study Completion Date : | March 1, 2024 |

Arm | Intervention/treatment |
---|---|
Experimental: JS001 alone
Subjects receive JS001 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
|
Drug: JS001
JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Other Name: Toripalimab Procedure: Thoracic Surgery Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy. |
Experimental: JS001+chemotherapy
Subjects receive JS001 240 mg, pemetrexed of 500 mg/m^2 and carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
|
Drug: JS001
JS001 was given 240 mg i.v. infusion on Day 1 of each 21-day cycle for 3 cycles.
Other Name: Toripalimab Drug: Pemetrexed Subjects receive pemetrexed of 500 mg/m^2 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Other Name: Pemetrexed Disodium Drug: Carboplatin Subjects receive carboplatin at the AUC of 5 administered as IV infusion on Day 1 of each 21-day cycle for 3 cycles.
Other Name: CBP Procedure: Thoracic Surgery Surgery will be performed at least 21 days after the last dose of neoadjuvant therapy. |
- 3-year Disease Free Survival [ Time Frame: 3 years after the last patient is registered ]Disease-free survival was assessed from registration to disease recurrence or death as a result of any cause.
- Number of participants with treatment-related adverse events (AEs) [ Time Frame: 2 years after the last patient is registered ]Adverse Events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0.
- Number of participants with perioperative complications [ Time Frame: 2 years ]Perioperative complications will be recorded
- 3-year Overall survival [ Time Frame: 3 years after the last patient is registered ]Overall survival was assessed from registration to death as a result of any cause.
- Pathologic Response [ Time Frame: 3 months ]To assess pathologic response to neoadjuvant JS001, or JS001 in combination with chemotherapy in resected tumor and lymph nodes. Major pathologic response was defined as <10% residual viable tumor cells in the resection specimen.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Target population is high risk NSCLC with resection option for potential cure, as assessed by a faculty surgeon at SYSUCC. This may include clinical stage IB (≥4cm), II and IIIA. Subjects with N3 nodal involvement are not included.
- Subjects should not have a previously detected sensitizing EGFR mutation or ALK fusion oncogene.
- Written informed consent provided.
- Male and female patients aged ≥18 years, < 75 years.
- Able to comply with the required protocol and follow-up procedures, and able to receive oral medications.
- Blood and specimens before and after treatment must be provided
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
- Life expectancy ≥12 weeks.
- Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level).
- Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN in subjects without liver metastases; ≤ 5 x ULN in subjects with liver metastases.
- Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min.
- Female subjects should not be pregnant or breast-feeding.
Exclusion Criteria:
- Known severe hypersensitivity to JS001 or any of the excipients of this product.
- Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody (including any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
- Prior chemotherapy or radiotherapy.
- Subjects with active, known or suspected autoimmune disease. Subjects in conditions not expected to recur in the absence of an external trigger, or not requiring systemic treatment are permitted to enroll.
- Subjects with a condition requiring systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of first administration of study treatment. Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
- Inability to comply with protocol or study procedures.
- A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study.
- A serious cardiac condition, such as myocardial infarction within 6 months, angina, or heart disease.
- History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
- Any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease).
- Patient who has active serious infection (e.g. pyrexia of or 38.0℃ over)
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
- Known history of active Hepatitis B or C.
- Women who are pregnant or nursing.
- Evidence of any other disease, neurological or metabolic dysfunction, physical examination or laboratory finding giving reasonable suspicion of a disease or condition that contraindicated the use of an investigational drug or puts the subject at high risk for treatment-related complications.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03623776
China, Guangdong | |
Sun Yat-sen University Cancer Center | |
Guangzhou, Guangdong, China, 510060 |
Principal Investigator: | Si-Yu Wang | Sun Yat-sen University |
Responsible Party: | Si-Yu Wang, Professor, Sun Yat-sen University |
ClinicalTrials.gov Identifier: | NCT03623776 |
Other Study ID Numbers: |
GASTO1038 |
First Posted: | August 9, 2018 Key Record Dates |
Last Update Posted: | March 14, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Non-Small Cell Lung Cancer Neoadjuvant Programmed Death-1 |
Carboplatin Pemetrexed Antineoplastic Agents Enzyme Inhibitors |
Molecular Mechanisms of Pharmacological Action Folic Acid Antagonists Nucleic Acid Synthesis Inhibitors |